246 lines
13 KiB
Markdown
246 lines
13 KiB
Markdown
---
|
|
lineage_type: import
|
|
upstream_source: https://github.com/mims-harvard/ToolUniverse/blob/e2520a96/skills/tooluniverse-spatial-omics-analysis/SKILL.md
|
|
upstream_sha: e2520a96
|
|
imported_at: 2026-06-26
|
|
prompt_class: prompt
|
|
upstream_changes: accepted
|
|
name: tooluniverse-spatial-omics-analysis
|
|
description: Spatial multi-omics interpretation pipeline. Transforms spatially variable genes (SVGs), domain annotations, and tissue context into biological insights via domain-by-domain characterization, cell-type composition, spatial gene expression patterns, RNA+protein+metabolite integration. Use for Visium, MERFISH, seqFISH, Slide-seq, spatial proteomics, and spatial multi-omics interpretation. Goes beyond statistics to disease mechanisms and therapeutic opportunities.
|
|
disable-model-invocation: true
|
|
---
|
|
|
|
# Spatial Multi-Omics Analysis Pipeline
|
|
|
|
Comprehensive biological interpretation of spatial omics data. Transforms spatially variable genes (SVGs), domain annotations, and tissue context into actionable biological insights.
|
|
|
|
**KEY PRINCIPLES**:
|
|
1. **Report-first approach** - Create report file FIRST, then populate progressively
|
|
2. **Domain-by-domain analysis** - Characterize each spatial region independently before comparison
|
|
3. **Gene-list-centric** - Analyze user-provided SVGs and marker genes with ToolUniverse databases
|
|
4. **Biological interpretation** - Go beyond statistics to explain biological meaning of spatial patterns
|
|
5. **Disease focus** - Emphasize disease mechanisms and therapeutic opportunities when disease context is provided
|
|
6. **Evidence grading** - Grade all evidence as T1 (human/clinical) to T4 (computational)
|
|
7. **Multi-modal thinking** - Integrate RNA, protein, and metabolite information when available
|
|
8. **Validation guidance** - Suggest experimental validation approaches for key findings
|
|
9. **Source references** - Every statement must cite tool/database source
|
|
10. **English-first queries** - Always use English terms in tool calls
|
|
|
|
---
|
|
|
|
## LOOK UP, DON'T GUESS
|
|
When uncertain about any scientific fact, SEARCH databases first (PubMed, UniProt, ChEMBL, ClinVar, etc.) rather than reasoning from memory. A database-verified answer is always more reliable than a guess.
|
|
|
|
---
|
|
|
|
## COMPUTE, DON'T DESCRIBE
|
|
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.
|
|
|
|
## When to Use This Skill
|
|
|
|
Apply when users:
|
|
- Provide spatially variable genes from spatial transcriptomics experiments
|
|
- Ask about biological interpretation of spatial domains/clusters
|
|
- Need pathway enrichment of spatial gene expression data
|
|
- Want to understand cell-cell interactions from spatial data
|
|
- Ask about tumor microenvironment heterogeneity from spatial omics
|
|
- Need druggable targets in specific spatial regions
|
|
- Ask about tissue zonation patterns (liver, brain, kidney)
|
|
- Want to integrate spatial transcriptomics + proteomics data
|
|
|
|
**NOT for**: Single gene interpretation (use target-research), variant interpretation, drug safety, bulk RNA-seq, GWAS analysis.
|
|
|
|
---
|
|
|
|
## Input Parameters
|
|
|
|
| Parameter | Required | Description | Example |
|
|
|-----------|----------|-------------|---------|
|
|
| **svgs** | Yes | Spatially variable genes | `['EGFR', 'CDH1', 'VIM', 'MYC', 'CD3E']` |
|
|
| **tissue_type** | Yes | Tissue/organ type | `brain`, `liver`, `lung`, `breast` |
|
|
| **technology** | No | Spatial omics platform | `10x Visium`, `MERFISH`, `DBiTplus` |
|
|
| **disease_context** | No | Disease if applicable | `breast cancer`, `Alzheimer disease` |
|
|
| **spatial_domains** | No | Domain -> marker genes dict | `{'Tumor core': ['MYC','EGFR']}` |
|
|
| **cell_types** | No | Cell types from deconvolution | `['Epithelial', 'T cell']` |
|
|
| **proteins** | No | Proteins detected (multi-modal) | `['CD3', 'PD-L1', 'Ki67']` |
|
|
| **metabolites** | No | Metabolites (SpatialMETA) | `['glutamine', 'lactate']` |
|
|
|
|
---
|
|
|
|
## Spatial Omics Integration Score (0-100)
|
|
|
|
**Data Completeness (0-30)**: SVGs (5), Disease context (5), Spatial domains (5), Cell types (5), Multi-modal (5), Literature (5)
|
|
|
|
**Biological Insight (0-40)**: Pathway enrichment FDR<0.05 (10), Cell-cell interactions (10), Disease mechanism (10), Druggable targets (10)
|
|
|
|
**Evidence Quality (0-30)**: Cross-database validation 3+ DBs (10), Clinical validation (10), Literature support (10)
|
|
|
|
| Score | Tier | Interpretation |
|
|
|-------|------|----------------|
|
|
| 80-100 | Excellent | Comprehensive characterization, strong insights, druggable targets |
|
|
| 60-79 | Good | Good pathway/interaction analysis, some therapeutic context |
|
|
| 40-59 | Moderate | Basic enrichment, limited domain comparison |
|
|
| 0-39 | Limited | Minimal data, gene-level annotation only |
|
|
|
|
### Evidence Grading
|
|
|
|
| Tier | Criteria | Examples |
|
|
|------|----------|----------|
|
|
| [T1] | Direct human/clinical evidence | FDA-approved drug, validated biomarker |
|
|
| [T2] | Experimental evidence | Validated spatial pattern, known L-R pair |
|
|
| [T3] | Computational/database evidence | PPI prediction, pathway enrichment |
|
|
| [T4] | Annotation/prediction only | GO annotation, text-mined association |
|
|
|
|
---
|
|
|
|
## Analysis Phases Overview
|
|
|
|
### Phase 0: Input Processing & Disambiguation (ALWAYS FIRST)
|
|
Resolve tissue/disease identifiers, establish analysis context. Get MONDO/EFO IDs for disease queries.
|
|
- Tools: `OpenTargets_get_disease_id_description_by_name`, `OpenTargets_get_disease_description_by_efoId`, `HPA_search_genes_by_query`
|
|
|
|
### Phase 1: Gene Characterization
|
|
Resolve gene IDs, annotate functions, tissue specificity, subcellular localization.
|
|
- Tools: `MyGene_query_genes`, `UniProt_get_function_by_accession`, `HPA_get_subcellular_location`, `HPA_get_rna_expression_by_source`, `HPA_get_comprehensive_gene_details_by_ensembl_id`, `HPA_get_cancer_prognostics_by_gene`, `UniProtIDMap_gene_to_uniprot`
|
|
|
|
### Phase 2: Pathway & Functional Enrichment
|
|
Identify enriched pathways globally and per-domain. Filter FDR < 0.05.
|
|
- Tools: `STRING_functional_enrichment` (PRIMARY), `ReactomeAnalysis_pathway_enrichment`, `GO_get_annotations_for_gene`, `kegg_search_pathway`, `WikiPathways_search`
|
|
|
|
### Phase 3: Spatial Domain Characterization
|
|
Characterize each domain biologically, assign cell types from markers, compare domains.
|
|
- Tools: Phase 2 tools + `HPA_get_biological_processes_by_gene`, `HPA_get_protein_interactions_by_gene`
|
|
|
|
### Phase 4: Cell-Cell Interaction Inference
|
|
Predict communication from spatial patterns. Check ligand-receptor pairs across domains.
|
|
- Tools: `STRING_get_interaction_partners`, `STRING_get_protein_interactions`, `intact_search_interactions`, `Reactome_get_interactor`, `DGIdb_get_drug_gene_interactions`
|
|
|
|
### Phase 5: Disease & Therapeutic Context
|
|
Connect to disease mechanisms, identify druggable targets, find clinical trials.
|
|
- Tools: `OpenTargets_get_associated_targets_by_disease_efoId`, `OpenTargets_get_target_tractability_by_ensemblID`, `OpenTargets_get_associated_drugs_by_target_ensemblID`, `search_clinical_trials`, `DGIdb_get_gene_druggability`, `civic_search_genes`
|
|
|
|
### Phase 6: Multi-Modal Integration
|
|
Integrate protein/RNA/metabolite data. Compare spatial RNA with protein detection.
|
|
- Tools: `HPA_get_subcellular_location`, `HPA_get_rna_expression_in_specific_tissues`, `Reactome_map_uniprot_to_pathways`, `kegg_get_pathway_info`
|
|
|
|
### Phase 7: Immune Microenvironment (Cancer/Inflammation only)
|
|
Classify immune cells, check checkpoint expression, assess Hot vs Cold vs Excluded patterns.
|
|
- Tools: `STRING_functional_enrichment`, `OpenTargets_get_target_tractability_by_ensemblID`, `iedb_search_epitopes`
|
|
|
|
### Phase 8: Literature & Validation Context
|
|
Search published evidence, suggest validation experiments (smFISH, IHC, PLA).
|
|
- Tools: `PubMed_search_articles`, `openalex_literature_search`
|
|
|
|
### Data Discovery: HuBMAP Spatial Atlas Tools
|
|
|
|
Use HuBMAP tools to find published spatial biology reference datasets for comparison, validation, or cross-study analysis.
|
|
|
|
| Tool | Purpose | Key Parameters |
|
|
|------|---------|----------------|
|
|
| `HuBMAP_search_datasets` | Search published spatial datasets by organ/assay/keyword | `organ` (code: "LK"=Kidney, "BR"=Brain, "LU"=Lung, etc.), `dataset_type` ("RNAseq", "CODEX", "MALDI"), `query`, `limit` |
|
|
| `HuBMAP_list_organs` | List all available organs with codes and UBERON IDs | (no required params) |
|
|
| `HuBMAP_get_dataset` | Get detailed metadata for a specific HuBMAP dataset | `hubmap_id` (e.g. "HBM626.FHJD.938") |
|
|
|
|
**When to use**: Phase 0 (find reference datasets for the tissue), Phase 8 (cross-reference findings with published HuBMAP atlas data).
|
|
|
|
See **phase-procedures.md** for detailed workflows, decision logic, and tool parameter specifications per phase.
|
|
|
|
---
|
|
|
|
## Report Structure
|
|
|
|
Create file: `{tissue}_{disease}_spatial_omics_report.md`
|
|
|
|
```
|
|
# Spatial Multi-Omics Analysis Report: {Tissue Type}
|
|
**Report Generated**: {date} | **Technology**: {platform}
|
|
**Tissue**: {tissue_type} | **Disease**: {disease or "Normal tissue"}
|
|
**Total SVGs**: {count} | **Spatial Domains**: {count}
|
|
**Spatial Omics Integration Score**: (calculated after analysis)
|
|
|
|
## Executive Summary
|
|
## 1. Tissue & Disease Context
|
|
## 2. Spatially Variable Gene Characterization
|
|
- 2.1 Gene ID Resolution
|
|
- 2.2 Tissue Expression Patterns
|
|
- 2.3 Subcellular Localization
|
|
- 2.4 Disease Associations
|
|
## 3. Pathway Enrichment Analysis
|
|
- 3.1 STRING, 3.2 Reactome, 3.3-3.5 GO (BP, MF, CC)
|
|
## 4. Spatial Domain Characterization (per-domain + comparison)
|
|
## 5. Cell-Cell Interaction Inference
|
|
- 5.1 PPI, 5.2 Ligand-Receptor, 5.3 Signaling Pathways
|
|
## 6. Disease & Therapeutic Context
|
|
- 6.1 Disease Gene Overlap, 6.2 Druggable Targets, 6.3 Drug Mechanisms, 6.4 Trials
|
|
## 7. Multi-Modal Integration (if data available)
|
|
## 8. Immune Microenvironment (if relevant)
|
|
## 9. Literature & Validation Context
|
|
## Spatial Omics Integration Score (breakdown table)
|
|
## Completeness Checklist
|
|
## References (tools used, database versions)
|
|
```
|
|
|
|
See **report-template.md** for full template with table structures.
|
|
|
|
---
|
|
|
|
## Completeness Checklist
|
|
|
|
- [ ] Gene ID resolution complete
|
|
- [ ] Tissue expression patterns analyzed (HPA)
|
|
- [ ] Subcellular localization checked (HPA)
|
|
- [ ] Pathway enrichment complete (STRING + Reactome)
|
|
- [ ] GO enrichment complete (BP + MF + CC)
|
|
- [ ] Spatial domains characterized individually
|
|
- [ ] Domain comparison performed
|
|
- [ ] PPI analyzed (STRING)
|
|
- [ ] Ligand-receptor pairs identified
|
|
- [ ] Disease associations checked (OpenTargets)
|
|
- [ ] Druggable targets identified
|
|
- [ ] Multi-modal integration performed (if data available)
|
|
- [ ] Immune microenvironment characterized (if relevant)
|
|
- [ ] Literature search completed
|
|
- [ ] Validation recommendations provided
|
|
- [ ] Integration Score calculated
|
|
- [ ] Executive summary written
|
|
- [ ] All sections have source citations
|
|
|
|
---
|
|
|
|
## Common Use Cases
|
|
|
|
1. **Cancer Spatial Heterogeneity**: Visium with tumor/stroma/immune domains -> pathways, immune infiltration, druggable targets, checkpoints
|
|
2. **Brain Tissue Zonation**: MERFISH with neuronal subtypes -> synaptic signaling, receptors, hippocampal zonation
|
|
3. **Liver Metabolic Zonation**: Periportal vs pericentral -> CYP450, Wnt gradient, drug metabolism enzymes
|
|
4. **Tumor-Immune Interface**: DBiTplus RNA+protein -> checkpoint L-R pairs, immune exclusion, multi-modal concordance
|
|
5. **Developmental Patterns**: Morphogen gradients (Wnt, BMP, FGF, SHH), TF patterns, cell fate genes
|
|
6. **Disease Progression**: Disease gradient -> inflammatory response, neuronal loss, therapeutic windows
|
|
|
|
---
|
|
|
|
## Reference Files
|
|
|
|
- **phase-procedures.md** - Detailed phase workflows, decision logic, tool usage per phase
|
|
- **tool-reference.md** - Tool parameter names, response formats, fallback strategies, limitations
|
|
- **reference-data.md** - Cell type markers, ligand-receptor pairs, immune checkpoint reference
|
|
- **report-template.md** - Full report template with all table structures
|
|
- **test_spatial_omics.py** - Test suite
|
|
|
|
---
|
|
|
|
## Summary
|
|
|
|
**Spatial Multi-Omics Analysis** provides:
|
|
1. Gene characterization (ID resolution, function, localization, tissue expression)
|
|
2. Pathway & functional enrichment (STRING, Reactome, GO, KEGG)
|
|
3. Spatial domain characterization (per-domain and cross-domain)
|
|
4. Cell-cell interaction inference (PPI, ligand-receptor, signaling)
|
|
5. Disease & therapeutic context (disease genes, druggable targets, trials)
|
|
6. Multi-modal integration (RNA-protein concordance, metabolic pathways)
|
|
7. Immune microenvironment (cell types, checkpoints, immunotherapy)
|
|
8. Literature context & validation recommendations
|
|
|
|
**Outputs**: Markdown report with Spatial Omics Integration Score (0-100)
|
|
**Uses**: 70+ ToolUniverse tools across 9 analysis phases
|
|
**Time**: ~10-20 minutes depending on gene list size
|